Emporium, Weinstock's, Bergdorf Goodman, Holt Renfrew?Canada, Waldenbooks, John Wanamaker, Thalhimers, & Sunset House. As president of Carter Hawley Hale Stores finance subsidiary, & VP & treasurer of the company, he was responsible for all finance, banking, & investment functions including mergers, acquisitions, & divestitures, an IPO, & corporate restructuring & re-capitalization.

William Butler is Executive VP. He was VP of business development & remains a board member for LiveToPlay.com, an e-commerce, business-to-consumer sports auction company. Previously, he was VP business development & sales strategy in the military division of Weber Distribution, a consumer packaged goods distributor to military commissaries & exchanges in the Western U.S. & Pacific Rim countries. He practiced business law for five years.

Financial Status

C-ME.com successfully completed its IPO 7/99. It has assets of over $2 million, primarily in cash, & liabilities of less than $300,000. Current assets are earmarked for implementation of its business strategy. A Form 10K for the year ending 6/30/99 is available upon request.

Recommendation

I recommend CMEE for midterm & long-term appreciation. It is automating the front-end retail sourcing process. This saves retailers & vendors money. Other things I like include:

• Extremely cost-effective for large retailers
• A must for small vendors o Unique service to a large market
• Pricing structure & strategic alliances are attractive to retailers & vendors
• Efficient, global sourcing of broad range of products
• User-friendly site encourages retailer & vendor use

Contact

Call Elissa Kuykendall @ 626-793-5000, fax 626-7936-5096, e-mail ir@C-ME.com, or write 600 S. Lake Ave., Suite 405, Pasadena CA 91106. www.C-ME.com

Industry Commentary

By Tony Velocci

Fear of breast cancer is shared by countless women, for whom physical self-examinations & periodic mammography probably are their best hope for early detection. But a more accurate procedure may be on the horizon.

BioLabs, Inc. (OTC Bulletin Board/BILB) of Surrey, B.C., in partnership with privately-held Biotherapies Inc. of Ann Arbor, Mich., is developing a test that measures the mammastatin levels in a woman's blood. Clinical evidence strongly suggests that mammastatin is a key protein that controls abnormal cancerous cell growth. It is present in the blood of healthy women & absent in at least 90% of breast cancer patients regardless of whether they have a family history of breast cancer.

The blood test offers medical professionals the potential opportunity to identify women with breast cancer before they otherwise would have been alerted using traditional methods. In addition to BioLabs' 11% equity interest in Biotherapies, the development-stage company also has a 50% interest in the joint venture to manufacture, market, & distribute the blood test. Biomedical Diagnostics LLC is the joint venture incorporated to bring to the product to market.

An estimated 186,000 women are diagnosed with breast cancer every year in the U.S. alone, & another 46,000 die. Currently, about one out of every eight women is expected to develop breast cancer in her lifetime. BioLabs, through the joint venture, expects to target three primary markets for the test: women over the age of 30 (420 million worldwide, including 50 million in the U.S.), breast cancer survivors (16 million worldwide, including 2.3 million in the U.S.), & breast cancer patients (4 million worldwide, including 700,000 in the U.S.).

Once the product is officially introduced, BioLabs President & CEO E. Greg McCarney believes that within five years up to half of the women in North America could include the blood test as part of their routine health care. The global market for breast cancer diagnostics & therapeutics is approximately $10 billion, he said.

Phase I & II clinical trials, which were approved by the Food & Drug Administration, are under way at MD Anderson Cancer Institute at the University of Texas in Houston. The scope of the trials has included safety testing & dose optimization studies of human mammary epithelial cell-derived mammastatin for use as a replacement therapy in refractory Stage IV breast cancer patients.

Preliminary laboratory research in more than 1,000 blood & breast tissue samples has consistently shown that mammastatin is a key protein for controlling abnormal cell growth in breast tissue samples. In addition, research on 29 late-stage breast cancer patients has demonstrated that mammastatin replacement therapy has been more than 70% effective in preventing breast cancer growth.

A major focus for BioLabs is strengthening the management team. The company's board of directors includes Carol Patterson Neves, who has more than 40 years of experience in financial markets. She formerly was senior research analyst in Diversified Markets for Merrill Lynch, Pierce, Fenner & Smith. She is

...continued on next page, click here

Disclaimer: The public companies featured in the Corporate Profiles listed in the "Special Situation" section on the Home Page of www.WallStreetCorner.com are our regular clients. Each such client pays an annual cash fee of $12,000, or alternatively, a monthly cash fee of $495 plus a negotiated number of Form 144 restricted shares for our service. We on rare occasions accept free-trading shares, but we usually hold such shares for the long pull - we do not engage in trading. Such fees are disclosed as part of the Corporate Profile prepared and posted on the particular company involved. The basic coverage provided to such clients primarily includes the preparation of their Corporate Profile, posting it here at WallStreetCorner.com, and the distribution of email alerts to our international database of investors and financial professionals when their Profile is initially posted, and each time their Profile is subsequently updated. We expect our clients to work with us in a team effort by calling us each time they have achieved a significant milestone. We then update their Profile and issue an additional email alert to our totally opt-in email database (as of July 2008, members of that database are from over 96 countries). The email distributions we make are a key element of our service -- those, as well as the updated Corporate Profile are what together are designed to achieve a gradual buildup of new shareholders who generally hold for the long term. If you are an officer at a public company and want the exposure afforded at WallStreetCorner.com, email Larry at up415@aol.com or call him at 843-645-2729. Information displayed by WallStreetCorner in its Corporate Profiles, and in its editorial or other columns, does not constitute an offer to buy, sell, or trade a security of any kind, including stock. Larry Oakley, and/or WallStreetCorner.com, Inc., does not recommend that any person, institution, or other entity make any decisions or form any opinions, etc. based on the information on this site. All visitors to this site are urged to do two things before investing in any stock: (1) Call the company and ask questions -- if there is anything you do not like regarding such call, pass -- our goal is to bring you a selection of what we feel are growth situations with good long-term appreciation potential, but you must accept the responsibility of making your own decisions regarding which situations to invest in -- do not give up that responsibility; and (2) Consult a qualified financial professional before taking any actions in regards to buying, selling, or trading securities (stocks or other forms of equity). Companies covered in Conservative Speculator, a newsletter accessed from WallStreetCorner, or in any of Larry Oakley's other editorial venues ("Opinion," "Stock Pick," "Comment," and "Bold Ventures" columns, and in any other editorial venue to which Larry contributes) do not pay for such editorial coverage; the companies Larry covers editorially have never, do not now, and never will be charged for editorial coverage. The only paid portions of WallStreetCorner.com are the Profiles and email distributions (email distributions are a part of the client's package, but occasionally are paid for separately by non-clients - if a non-client wants to utilize our email distributions, the cost is $2,000 for the first distribution, $1,500 for the second, $1,000 for the third, and $500 for all subsequent distributions made for the same company). On occasion, Larry Oakley shares his opinion regarding a private company or its product or service. Bear in mind that nothing at that special section is an investment possibility. To see that section, click where on the home page it says: "Click here to access our Special Emerging Growth Situations." See the introductory portion of that special section for additional information regarding the material covered there.

WallStreetCorner.com
WallStreetCorner.com, Inc.